Based on these preclinical data, the particularly high expression of IL18BP in ccRCC (12), and the demonstrated responsiveness of RCC to ICIs and other cytokine-based immunotherapies, we hypothesized that IL-18 could be an effective cytokine for treating aRCC. This evidence concerns the gene IL18BP and renal cell carcinoma.